Related Experiment Video

Updated: Apr 7, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Jiang Chen1, Renan Jin1, Jie Zhao1

  • 1Department of General Surgery, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang, China.

Cancer Letters
|July 15, 2015
PubMed

Insights

Sorafenib resistance in advanced hepatocellular carcinoma is a growing concern due to varied patient responses. This study reviews molecular, cellular, and microenvironmental factors contributing to sorafenib resistance.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sorafenib is a standard treatment for advanced hepatocellular carcinoma.
  • Resistance to sorafenib is a significant clinical challenge.
  • Individual responses to sorafenib vary greatly, highlighting treatment heterogeneity.

Purpose of the Study:

  • To provide a comprehensive overview of sorafenib resistance mechanisms in hepatocellular carcinoma.
  • To explore potential molecular, cellular, and microenvironmental factors involved in resistance.
  • To synthesize existing research for a systemic insight into the problem.

Main Methods:

  • Systematic review of previous studies and reports on sorafenib resistance.
  • Analysis of molecular mechanisms contributing to impaired sensitivity.
  • Evaluation of cellular and microenvironmental factors influencing treatment response.

Main Results:

  • Sorafenib resistance is multifactorial, involving complex interactions.
  • Molecular alterations, cellular plasticity, and the tumor microenvironment play crucial roles.
  • Heterogeneity in these factors contributes to diverse patient outcomes.

Conclusions:

  • Understanding the diverse mechanisms of sorafenib resistance is critical for developing effective therapeutic strategies.
  • Targeting molecular, cellular, and microenvironmental pathways may overcome resistance.
  • Further research is needed to elucidate specific resistance pathways and identify novel therapeutic targets.
Keywords:
Acquired resistanceAdvanced hepatocellular carcinoma (HCC)Cancer stem cells (CSCs)Epithelial–mesenchymal transitions (EMT) and mesenchymal–epithelial transitions (MET)Microenvironment

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

635
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.2K